Watchlist Price Alert

Ovid Therapeutics Inc. (OVID)

NASDAQ: OVID · Real-Time Price · USD

0.30

0.01 (4.90%)

At close: May 14, 2025, 3:58 PM

0.29

-0.17%

After-hours: May 14, 2025, 06:40 PM EDT

4.90% (1D)

Bid	0.29
Market Cap	21.01M
Revenue (ttm)	566K
Net Income (ttm)	-26.43M
EPS (ttm)	-0.37
PE Ratio (ttm)	-0.8
Forward PE	-0.67
Analyst	Buy

Ask	0.35
Volume	188,815
Avg. Volume (20D)	379,131
Open	0.31
Previous Close	0.29
Day's Range	0.29 - 0.31
52-Week Range	0.24 - 3.43
Beta	0.27

About OVID

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol OVID

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for OVID stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Ovid Therapeutics has released their quartely earnings on May 13, 2025:

Revenue of $130K exceeds estimates by $96.67K, with -12.16% YoY decline.

EPS of -0.14 misses estimates by -0.01, with 17.65% YoY growth.

Why Price Moved

1 day ago New

+3.11%

Ovid Therapeutics shares are trading higher after ... Unlock content with Pro Subscription

11 months ago

-76%

Ovid Therapeutics shares are trading lower after Takeda's Skyline study in Dravet syndrome missed its primary endpoint

News

1 day ago · zacks.com

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.

1 week ago · zacks.com

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · zacks.com

Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.22 per share a year ago.